Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Ferdinandos SkoulidisBob T LiGrace K DyTimothy J PriceGerald S FalchookJürgen WolfAntoine ItalianoMartin SchulerHossein BorghaeiFabrice BarlesiTerufumi KatoAlessandra Curioni-FontecedroAdrian SacherAlexander SpiraSuresh S RamalingamToshiaki TakahashiBenjamin BesseAbraham AndersonAgnes AngQui TranOmar MatherHaby HenaryGataree NgarmchamnanrithGregory FribergVamsidhar VelchetiRamaswamy GovindanPublished in: The New England journal of medicine (2021)
In this phase 2 trial, sotorasib therapy led to a durable clinical benefit without new safety signals in patients with previously treated KRAS p.G12C-mutated NSCLC. (Funded by Amgen and the National Institutes of Health; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).